Literature DB >> 6966993

Expression of blood group-like antigens on the T lymphocytes of acute leukaemia patients in remission.

S Pullen, P Hersey.   

Abstract

A number of previous studies have described antibodies in normal sera reactive to human leukaemia cells. In the course of studies on humoral immunity to acute myeloid leukaemia (AML) cells it was noticed that sera from normal subjects were cytotoxic in complement lysis and leucocyte dependent antibody (LDA) assays to blood leucocytes from patients with AML in remission. Investigation of these reactions in eleven patients with acute leukaemia in complete or partial remission revealed that reactivity occurred most frequently between sera from normal blood group O or B subjects and leucocytes from patients of blood group A (five patients). Leucocytes from blood group O patients were largely unreactive. Blood leucocytes from five of six patients in relapse did not react with normal sera. Subsequent studies revealed that the antigens were detected only on T lymphocytes. Reactivity could be removed by absorption on red cells of blood group A but not sheep or Ox red blood cells suggesting the antigens concerned were closely related to blood group A antigens. Some reactivity with antisera to the blood group H antigens was also evident in these studies. Gel filtration studies indicated that lymphocyte dependent antibody mediated cytotoxicity was mediated by IgG antibodies while complement dependent lysis was mainly mediated by IgM antibodies. The biological significance of these findings has yet to be determined but these results suggest that reactivity with blood group antigens needs to be considered in in vitro cytotoxicity studies involving leucocytes from leukaemia patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966993      PMCID: PMC1538051     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Characterization of mononuclear effector cells in human blood.

Authors:  P Hersey; A Edwards; J Edwards
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

2.  An improved rosetting assay for detection of human T lymphocytes.

Authors:  M E Kaplan; C Clark
Journal:  J Immunol Methods       Date:  1974-07       Impact factor: 2.303

3.  Immune function at diagnosis in relation to responses to therapy in acute lymphocytic leukemia of childhood.

Authors:  D G Jose; H Ekert; J Colebatch; K Waters; F Wilson; D O'Keefe
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

4.  Human antisera detecting leukemia-associated antigens on autochthonous tumor cells.

Authors:  D L Mann; B Leventhal; R Halterman
Journal:  J Natl Cancer Inst       Date:  1975-02       Impact factor: 13.506

5.  Blood group MN precursors as human breast carcinoma-associated antigens and "naturally" occurring human cytotoxins against them.

Authors:  G F Springer; P R Desai; E F Scanlon
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

6.  Specificity of cell-mediated cytotoxicity against human melanoma lines: evidence for "non-specific" killing by activated T-cells.

Authors:  P Hersey; A Edwards; J Edwards; E Adams; G W Milton; D S Nelson
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396

7.  Cytotoxic antibodies to human leukaemia cells in normal human sera.

Authors:  J F Dore; C Guibout; J Bertoglio; A Liabeuf
Journal:  Biomedicine       Date:  1976-12-30

8.  Normal human sera cytotoxic to cells of human acute leukemia.

Authors:  B Schacter; W B Bias; R L Humphrey
Journal:  Tissue Antigens       Date:  1976-11

9.  Isoantigenic expression of Forssman glycolipid in human gastric and colonic mucosa: its possible identity with "A-like antigen" in human cancer.

Authors:  S Hakomori; S M Wang; W W Young
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

10.  Blocking factors against leucocyte-dependent melanoma antibody in the sera of melanoma patients.

Authors:  E Murray; W H McCarthy; P Hersey
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.